Trial reportBMJ (Clinical research ed.)2010
Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial.
Trial report in BMJ (Clinical research ed.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 51 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Duration of Maintenance Anti-psychotic Therapy After First -Episode Schizophrenia: a Double-blind Randomized Placebo-control Relapse Prevention Study
Navigating the Longitudinal Effects of Early Treatment Strategies and Relapse on Clinical, Cognitive, and Functional Outcomes: A 20-Year Follow-up of First Episode Psychosis
Who cites it
51 citing papers in PubMed, 8 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- The effects of antipsychotic discontinuation or maintenance on the process of recovery in remitted first-episode psychosis patients - A systematic review and meta-analysis of randomized controlled trials.European psychiatry : the journal of the Association of European Psychiatrists · 2024Pooled it
- Examination of Dosing of Antipsychotic Drugs for Relapse Prevention in Patients With Stable Schizophrenia: A Meta-analysis.JAMA psychiatry · 2021Pooled it
- Achieving better outcomes for schizophrenia patients in Hong Kong: Strategies for improving treatment adherence.CNS neuroscience & therapeutics · 2021Pooled it
- Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Maintenance treatment with antipsychotic drugs for schizophrenia.The Cochrane database of systematic reviews · 2020Pooled it
- Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium.Biological psychiatry · 2018Pooled it
- Pooled it
- Acetylcholinesterase inhibitors for schizophrenia.The Cochrane database of systematic reviews · 2012Pooled it
- Guided antipsychotic reduction to reach minimum effective dose (GARMED) in patients with remitted psychosis: a 2-year randomized controlled trial with a naturalistic cohort.Psychological medicine · 2023Trial
- Factors Associated With Successful Medication Discontinuation After a Randomized Clinical Trial of Relapse Prevention in First-Episode Psychosis: A 10-Year Follow-up.JAMA psychiatry · 2019Trial
- Dopamine synthesis capacity in patients with remitted psychosis: correlates and one year outcome on relapse.European archives of psychiatry and clinical neuroscience · 2026Article
- Factors Affecting Continuation of Aripiprazole Long-acting Injection in the Real World.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2025Article
- Trials evaluating drug discontinuation: a scoping review sub-analysis focusing on outcomes and research questions.BMC medical research methodology · 2025Article
- Spurious autobiographical memories of psychosis: a dopamine-gated neuroplasticity account for relapse and treatment-resistant psychosis.Psychological medicine · 2025Review
- Predictors of relapse after discontinuing antipsychotics in patients with schizophrenia spectrum disorders.Schizophrenia (Heidelberg, Germany) · 2025Article
- Effects of mindfulness-based intervention in preventing relapse in patients with remitted psychosis: a randomized controlled trial.Schizophrenia (Heidelberg, Germany) · 2024Article
- Gender differences in the prevalence and clinical correlates of suicide attempts in young first-episode drug-naïve major depressive disorder patients with thyroid dysfunction.BMC psychiatry · 2024Article
- Clinical experiences of guided tapering of antipsychotics for patients with schizophrenia- a case series.BMC psychiatry · 2024Article
- Article
- Functional and clinical outcomes of delusional disorder and schizophrenia patients after first episode psychosis: a 4-year follow-up study.BMC psychiatry · 2023Article
Corrections and comments
- Commented on by
Authors and funding
15 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo study rates of relapse in remitted patients with first episode psychosis who either continued or discontinued antipsychotic drugs after at least one year of maintenance treatment.
design12 month randomised, double blind, placebo controlled trial.
settingEarly psychosis outpatient clinics in Hong Kong.
participants178 patients with first episode psychosis who had received at least one year of antipsychotic drug treatment between September 2003 and July 2006 and had no positive symptoms of psychosis.
interventionsPatients received either maintenance treatment with quetiapine (400 mg/day) or placebo and were followed up for the next 12 months or until a relapse occurred.
main outcome measureRelapse assessed monthly and defined as re-emergence of psychotic symptoms (delusions, conceptual disorganisation, hallucinations, suspiciousness, and unusual thought content) according to predefined thresholds.
results178 patients were randomised (89 to quetiapine and 89 to placebo). The Kaplan-Meier estimate of the risk of relapse at 12 months was 41% (95% confidence interval 29% to 53%) for the quetiapine group and 79% (68% to 90%) for the placebo group (P<0.001). Although quetiapine was generally well tolerated, the rate of discontinuation due to adverse or serious adverse events was greater in the quetiapine group (18%; 16/89) than in the placebo group (8%; 7/89) (relative risk 2.29, 95% confidence interval 0.99 to 5.28; chi(2)=3.20, df=1; P=0.07).
conclusionIn a group of asymptomatic patients with first episode psychosis and at least one year of previous antipsychotic drug treatment, maintenance treatment with quetiapine compared with placebo resulted in a substantially lower rate of relapse during the following year. Trial registration Clinical trials NCT00334035.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.